Last updated: April 23, 2026
Who Supplies Dolutegravir Sodium for Pharmaceutical Manufacturing?
Dolutegravir sodium is supplied through two primary channels: (1) active pharmaceutical ingredient (API) manufacturers of the small-molecule integrase inhibitor, and (2) certified chemical/API distributors that source from those manufacturers and supply finished API quantities, grades, and regulatory documentation.
What suppliers make dolutegravir sodium API?
The core supplier set for dolutegravir sodium API typically includes chemical and API manufacturers with small-molecule production platforms. A practical supplier list for sourcing is built from publicly indexed API manufacturers and distributors that publish drug master file (DMF) or regulatory support capabilities, plus firms that sell dolutegravir sodium under standard commercial grades (USP/EP-comparable specifications) for global customers.
Manufacturer and distributor categories to target for dolutegravir sodium
- API manufacturers (direct): make and sell dolutegravir sodium as API with batch COAs, impurity profiles, and quality system documentation.
- API distributors (channel): sell dolutegravir sodium sourced from one or more API manufacturers, with documentation packaging for customer qualification.
Which supplier types are most suitable for regulatory supply?
For R&D, clinical, and commercial manufacturing, supplier selection usually hinges on documentation completeness and supply qualification readiness.
| Supplier type |
Typical deliverables |
Best fit |
| API manufacturer |
Full impurity set, CoA, manufacturing process documentation support, DMF/CEP availability depending on jurisdiction |
Product development, ANDA/filing readiness |
| Authorized distributor |
Manufacturer CoA pass-through, often consolidated regulatory paperwork, supply continuity |
Clinical sourcing, fast timeline procurement |
How to shortlist dolutegravir sodium suppliers (qualification-ready criteria)
Dolutegravir sodium sourcing should be narrowed to suppliers that consistently support the following:
| Qualification requirement |
What to verify |
| Regulatory support |
DMF/CEP availability (where applicable), ability to support regulatory submissions |
| Quality documentation |
Batch COAs for each lot, impurity profile aligned to your specification, stability summaries if requested |
| Supply reliability |
Ability to deliver repeat lots, forecasted lead times, change control notifications |
| Analytical capability |
Capability to provide method suitability packages or support customer testing |
What does a typical dolutegravir sodium API specification screening include?
Supplier specs vary, but qualification teams usually screen against common acceptance parameters for integrase inhibitor APIs, including:
- Identity: chromatographic identity confirmation (e.g., HPLC/UPLC)
- Purity: assay on active substance
- Impurities: aligned impurity limits plus unspecified impurities
- Water/solvent: residual solvent class compliance and water content
- Solid-state: polymorph control if relevant to your process and formulation pathway
What documentation should suppliers provide for dolutegravir sodium?
A qualification-ready supplier package typically includes:
- Certificate of Analysis (CoA) for the specific batch
- SDS and manufacturing site quality statement
- Specification sheet (assay, impurities, residual solvents, water, microbiological parameters if requested)
- Impurity profiling (listing identified impurities and limits)
- Stability data (as available), or at minimum a stability commitment statement
What sourcing path fits commercial production?
For commercial-scale manufacturing, a supplier should support:
- Change control transparency (process, site, solvent, equipment, or impurity trend changes)
- Lot-to-lot consistency demonstrated by impurity trend data
- Regulatory traceability for DMF/CEP-linked information where required
Key Takeaways
- Dolutegravir sodium is supplied through API manufacturers and distributor channels; the choice determines how quickly you can qualify material for regulated manufacturing.
- Qualification should be driven by DMF/CEP/regulatory support, batch CoAs with impurity profiles, and demonstrated lot-to-lot consistency.
- Commercial sourcing requires strong change control and impurity trend documentation, not just price and lead time.
FAQs
1) Can dolutegravir sodium be sourced from distributors without loss of regulatory readiness?
Yes, if the distributor provides the API manufacturer’s lot-specific CoA and regulatory documentation package, and if the underlying API supplier supports DMF/CEP-linked traceability.
2) What is the most critical screening item when comparing dolutegravir sodium suppliers?
Impurity profiling and lot-to-lot consistency. Price matters after impurity and documentation alignment.
3) Do suppliers need to provide DMF for dolutegravir sodium?
For many regulated submission pathways, DMF linkage (or an equivalent regulatory support dossier such as CEP where applicable) is the decisive factor for filing readiness.
4) What documentation should be non-negotiable for clinical or commercial qualification?
Lot-specific CoA, current specification sheet, and impurity profile aligned to your acceptance criteria.
5) What quality-system evidence reduces supplier-change risk?
Documented change control processes and demonstrated batch-to-batch stability or impurity trend reporting.
References
[1] FDA. Drug Master Files (DMF) information and guidance. U.S. Food and Drug Administration. https://www.fda.gov/drugs/delivery-innovation/drug-master-files-dmf
[2] European Medicines Agency. European Medicines Agency: Certificates of Suitability (CEP) and related regulatory framework. https://www.ema.europa.eu/en/human-regulatory/overview/certificates-suitability-pharmaceutical-products-cep
[3] US EPA. SDS requirements and chemical safety documentation framework. https://www.epa.gov/chemical-research/safety-data-sheets-sds
